Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Amongst various cancer diseases, breast cancer is frequently diagnosed malignancy in women. Existing treatments are inadequate, painful and toxic. New ways of treatments need to be explored.
METHODS: The present work proposes preparation and targeted delivery of a formulation, F-1, for MCF-7 breast cancer treatment. The formulation, colloidal silver (0.76 ppm), was prepared by electrolytic deposition technique and multi surface coatings. Black tea extract (2.25%v/v) was used as a capping agent to tune the morphology of silver nanoparticle and potato extract (6.25%v/v) as a functionalizing agent for targeting MCF-7 breast cancer site.
RESULTS: Characterization results show highly pure spherical silver nanoparticles with an average particle size of 15nm. The shift of peaks in the FTIR spectra of formulation confirms the interaction between nanoparticles and extracts. The UV-visible peak was obtained at 525nm, a typical characteristic of silver nanoparticles. In-vivo; anti-cancer study of formulation gave a moderate therapeutic effect in Non-Obese Diabetic Severe Combined Immune Deficiency (NOD-SCID) mice.
CONCLUSION: It is observed that tumor volumes obtained in the case of Formulation-1 were moderately inhibited from days 5 to 9. However, one of the mice in the Formulation-1 group inhibited tumor volume to 1.52 cc similar to one of the mice of positive control group (Adriamycin 1.42cc).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current drug delivery - 17(2020), 7 vom: 18., Seite 613-621 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rajawat, Shweta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.07.2021 Date Revised 05.07.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1567201817666200508095241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30967283X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30967283X | ||
| 003 | DE-627 | ||
| 005 | 20231225134430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1567201817666200508095241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM30967283X | ||
| 035 | |a (NLM)32384028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rajawat, Shweta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2021 | ||
| 500 | |a Date Revised 05.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Amongst various cancer diseases, breast cancer is frequently diagnosed malignancy in women. Existing treatments are inadequate, painful and toxic. New ways of treatments need to be explored | ||
| 520 | |a METHODS: The present work proposes preparation and targeted delivery of a formulation, F-1, for MCF-7 breast cancer treatment. The formulation, colloidal silver (0.76 ppm), was prepared by electrolytic deposition technique and multi surface coatings. Black tea extract (2.25%v/v) was used as a capping agent to tune the morphology of silver nanoparticle and potato extract (6.25%v/v) as a functionalizing agent for targeting MCF-7 breast cancer site | ||
| 520 | |a RESULTS: Characterization results show highly pure spherical silver nanoparticles with an average particle size of 15nm. The shift of peaks in the FTIR spectra of formulation confirms the interaction between nanoparticles and extracts. The UV-visible peak was obtained at 525nm, a typical characteristic of silver nanoparticles. In-vivo; anti-cancer study of formulation gave a moderate therapeutic effect in Non-Obese Diabetic Severe Combined Immune Deficiency (NOD-SCID) mice | ||
| 520 | |a CONCLUSION: It is observed that tumor volumes obtained in the case of Formulation-1 were moderately inhibited from days 5 to 9. However, one of the mice in the Formulation-1 group inhibited tumor volume to 1.52 cc similar to one of the mice of positive control group (Adriamycin 1.42cc) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adriamycin | |
| 650 | 4 | |a MCF-7 breast cancer | |
| 650 | 4 | |a black tea leaves extract | |
| 650 | 4 | |a multi surface coatings | |
| 650 | 4 | |a potato extract | |
| 650 | 4 | |a silver nanoparticles | |
| 650 | 4 | |a targeted delivery | |
| 650 | 7 | |a Plant Extracts |2 NLM | |
| 650 | 7 | |a Polyphenols |2 NLM | |
| 650 | 7 | |a colloidal silver |2 NLM | |
| 650 | 7 | |a Silver |2 NLM | |
| 650 | 7 | |a 3M4G523W1G |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 700 | 1 | |a Malik, Manzar M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug delivery |d 2004 |g 17(2020), 7 vom: 18., Seite 613-621 |w (DE-627)NLM159100232 |x 1875-5704 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2020 |g number:7 |g day:18 |g pages:613-621 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1567201817666200508095241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2020 |e 7 |b 18 |h 613-621 | ||